Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liatermin - MedGenesis Therapeutix

Drug Profile

Liatermin - MedGenesis Therapeutix

Alternative Names: BVF-014; GDNF; Glial-derived neutrotrophic factor; r-metHuGDNF

Latest Information Update: 11 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; MedGenesis Therapeutix
  • Class Antiparkinsonians; Biological proteins; Nerve growth factors; Neuroprotectants
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease
  • Preclinical Inborn genetic disorders; Peripheral nerve injuries
  • Discontinued Amyotrophic lateral sclerosis; Deafness; Epilepsy; Pain; Sensorineural hearing loss

Most Recent Events

  • 11 Sep 2018 Discontinued - Preclinical for Epilepsy in Canada (Parenteral)
  • 11 Sep 2018 Discontinued - Preclinical for Sensorineural hearing loss in Canada (Parenteral)
  • 11 Sep 2018 Preclinical trials in Inborn genetic disorders in Canada (Parenteral) (MedGenesis pipeline, September 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top